ArticleSurgical endoscopy2026
Biomarker-guided perioperative inflammatory modulation and immunometabolic support are associated with improved recovery and survival after ultra-low anterior resection: a prospective nonrandomized controlled cohort study.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUltra-low anterior resection (ULAR) preserves sphincter function for low rectal cancer but often causes bowel, sexual, sleep, and psychological dysfunction, impairing recovery and survival. Persistent inflammation and immunometabolic dysregulation contribute significantly. We evaluated whether perioperative inflammatory modulation plus biomarker-guided immunometabolic support improved recovery and outcomes after ULAR.
methodsIn this prospective nonrandomized cohort, 198 patients with stage I-III rectal adenocarcinoma (April 2021-April 2023) received ERAS care or a biomarker-guided multicomponent targeted intervention combining perioperative inflammatory modulation and immunometabolic support. The intervention began 14 days preoperatively and continued 6 months, combining short-chain fatty acids, probiotics, and ω-3 fatty acids guided by C-reactive protein, interleukin-6, and tumor necrosis factor-α with individualized optimization (T-cell profiling, skeletal muscle preservation, tailored nutrition). Primary endpoints were depressive symptoms (BDI-II), sleep quality (PSQI), sexual function (IIEF-5/FSFI), and anorectal function (LARS) over 24 months. Secondary endpoints included inflammatory markers, skeletal muscle index (SMI), and survival.
resultsThe intervention improved BDI-II (- 4.5), PSQI (- 3.3), IIEF-5 (+ 4.9), FSFI (+ 5.4), and LARS (- 6.8; all p < 0.01), with 69.2% achieving composite response versus 35.4% of controls. Day-7 CRP, IL-6, and TNF-α were lower; T-cell recovery enhanced; and SMI decline attenuated (- 1.2% vs. - 3.8%; p < 0.001). Recovery accelerated, hospitalization shortened, and complications decreased. At 25.3 months, 2-year DFS (91.0% vs. 77.1%; HR 0.44; p = 0.015) and OS (94.6% vs. 82.3%; HR 0.39; p = 0.018) were higher.
conclusionA biomarker-guided perioperative program integrating inflammatory modulation and immunometabolic support was associated with improved multidomain recovery and survival after ULAR. Confirmation in randomized multicenter trials is warranted.
Indexed as
Identifiers
41162755What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.